November 23rd 2024
FDA's approval will allow Kedrion to manufacture Ryplazim (plasminogen, human-tvmh), the only FDA-approved therapy for treating PLGD-1, at facility in Bolognana, Italy.
November 19th 2024
It is important to understand the differences between risk-based decision making and other decision making in a pharmaceutical quality system.
PhRMA Seeks Policy Changes to Proposed Russian Pharmaceutical Law
March 11th 2010The Pharmaceutical Research and Manufacturers of America, along with eight other pharmaceutical, business, and trade organizations, are calling on Russian authorities to consider policy changes concerning clinical-trial regulation and intellectual property.